A mutation in the protein mitofusin 2 had been known to cause one type of CMT, a common inherited neurological disorder characterized by a loss of muscle tissue and sensation in the limbs, which affects about 2.6 million people. In this study, a team of researchers lead by Robert Baloh, MD, PhD, of Washington University School of Medicine, examined the role of mitofusin proteins in the cell to learn more precisely how the mutation causes the disease.

"Our study provides the first evidence that mitofusins directly regulate the movement of mitochondria in nerve fibers," Baloh said. "Furthermore, our work suggests the basis for this particular form of CMT is the abnormal movement of mitochondria in these fibers."

Mitochondria are dynamic cellular power providers that travel to places in the cell where energy is needed. All this activity hinges on a series of molecular signals that regulate where mitochondria go.

Baloh and his colleagues used images of live cells taken from mice to study the movement of mitochondria, which moved slower in cells with mutated mitofusin 2, suggesting that the protein directly affects their transport. Until now, researchers had been unsure as to whether the abnormality lay in their transport along, or attachment to, nerve fibers.

"This discovery places this type of CMT in the ever-growing list of neurodegenerative diseases caused by transport problems and strengthens the possibility of using general enhancers of this process as therapy for different types of diseases," said Vincent Timmerman, PhD, of the University of Antwerp in Belgium, who was unaffiliated with the study.

The authors also suggest that a related protein called mitofusin 1 might someday serve to compensate for a mutated and malfunctioning mitofusin 2. Although mitofusins 1 and 2 are different proteins, they play similar roles in a cell. Baloh and his team suggest that mitofusin 1 may be able to perform the function of mitofusin 2 and regulate the transport of mitochondria. Finding a way to increase the levels of mitofusin 1 might have therapeutic effects for patients who have mutated mitofusin 2.

The research was supported by the National Institute of Neurological Disorders and Stroke, the Neuroscience Blueprint Core Grant to Washington University, the Hope Center for Neurological Disorders, the Ministry of Health, Labour, and Welfare of Japan, the Muscular Dystrophy Association, and the Children's Discovery Institute.

Note: If no author is given, the source is cited instead.

• Nervous System
• Diseases and Conditions
• Parkinson's Research
• Amyotrophic Lateral Sclerosis
• Sickle Cell Anemia
• Cystic Fibrosis

• Skeletal muscle
• Programmed cell death
• Ketone bodies
• Huntington's disease
• Radical (chemistry)
• Myelin